Business Context and Reporting Period
Company: Inotiv, Inc. (NOTV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended June 30, 2025
Business Overview: Inotiv is a leading contract research organization (CRO) providing nonclinical and analytical drug discovery services and selling research-quality animals and diets. Operations are reported in two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 |
Nine Months Ended June 30, 2025 |
Nine Months Ended June 30, 2024 |
|---|---|---|---|
| Total Revenue | $130,683 | $374,882 | $360,322 |
| Operating Loss | $(5,675) | $(24,120) | $(73,239) |
| Net Loss | $(17,577) | $(60,073) | $(89,994) |
| Diluted EPS | $(0.51) | $(1.89) | $(3.46) |
| Cash and Equivalents (End of Period) | $6,215 | $6,215 | $14,434 |
| Total Debt (Net of issuance costs) | $396,542 | $396,542 | $393,339 |
| Operating Cash Flow | N/A | $(24,760) | $(4,433) |
Segment Performance (Nine Months Ended June 30, 2025):
- DSA: Revenue $136,304; Operating Income $4,039.
- RMS: Revenue $238,578; Operating Income $16,625 (vs. Operating Loss of $(32,973) in prior year).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 23.5% year-over-year for the quarter and 4.0% for the nine-month period. The quarter's growth was driven by a 34.1% increase in RMS revenue (higher NHP volumes and prices) and an 8.9% increase in DSA revenue.
- Profitability Improvement: Net loss narrowed significantly to $17.6M for the quarter (13.5% of revenue) from $26.1M (24.7% of revenue) in the prior year quarter. The nine-month net loss decreased to $60.1M from $90.0M.
- Unusual Items: The prior year nine-month period included a $28.5M charge related to the Resolution Agreement and Plea Agreement with the DOJ, which did not repeat in the current period. Conversely, the current period included a $7.55M settlement gain from Freese and Nichols, Inc.
- Inventory Build: Inventories increased by $26.8M year-over-year, primarily due to increased Non-Human Primate (NHP) research model inventory.
- Interest Expense: Interest expense increased due to the issuance of 15.00% Senior Secured Second Lien PIK Notes in September 2024.
Guidance, Outlook, Risks, and Contingencies
Liquidity and Going Concern
The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern. While management forecasts compliance with financial covenants for the next twelve months, the Company had negative operating cash flows and net losses. If results do not improve, the Company risks non-compliance with its Credit Agreement, which could trigger an event of default and acceleration of debt.
Debt and Covenants
The Company is subject to a Seventh Amendment to its Credit Agreement (Sept 2024), which established new testing ratios for the Fixed Charge Coverage Ratio and First Lien Leverage Ratio effective June 30, 2025. The Company was in compliance as of June 30, 2025. Total debt obligations include Term Loans, Convertible Senior Notes, and Second Lien Notes.
Legal and Regulatory Risks
- SEC Investigation: The SEC concluded its investigation into NHP importations and does not intend to recommend an enforcement action.
- DOJ Resolution: The Company is subject to a Resolution Agreement and Plea Agreement regarding a canine breeding facility, requiring fines totaling $22M and a five-year compliance monitorship.
- Litigation: A $10M liability has been accrued for securities class action and derivative lawsuits, with a corresponding $10M insurance recovery receivable recorded.
- Tariffs: Imported NHPs are subject to 10% tariffs, with future imports expected to face 15%-20% tariffs, negatively impacting cash flows.
Operational Outlook
Management plans to optimize capital allocation, increase NHP-related revenue through pre-selling inventory, and execute "Phase Two" of its site optimization program to achieve annual cost savings of $6M-$7M by March 2026.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to meet financial covenants under the Credit Agreement in the next 12 months given the explicit "substantial doubt" disclosure.
- Cash Burn Rate: Monitor the $24.8M negative operating cash flow for the nine months and the decline in cash balances from $21.4M to $6.2M.
- Debt Structure: Review the terms of the 15% Second Lien Notes and the impact of PIK (Payment-in-Kind) interest on future leverage ratios.
- Inventory Valuation: Assess the $45.1M inventory balance, specifically the $41.2M in research model inventory, for potential obsolescence or valuation risks given tariff headwinds.
- Litigation Resolution: Track the status of the securities class action lawsuits to confirm if the $10M insurance recovery is fully realizable.
- Tariff Impact: Evaluate the Company's ability to pass on increased 15%-20% NHP tariff costs to customers without losing volume.